Development of Psoriasis Assessment Tools Among Patients in the CorEvitas Psoriasis Registry
Wayne Gulliver, Kyoungah See, Baojin Zhu, Bruce W. Konicek et autres
1 citationJournal of Psoriasis and Psoriatic Arthritis
Craig L. Leonardi
Informations fournies par OpenAlex. Research Africa ne déduit ni nationalité, ni poste, ni coordonnées personnelles.
173Publications signalées
21716Citations signalées
1Affiliations récentes
Institutions déclarées
Domaines associés
Psoriasis: Treatment and PathogenesisSpondyloarthritis Studies and TreatmentsDermatology and Skin DiseasesPharmaceutical studies and practicesAutoimmune Bullous Skin Diseases
Publications récentes
Brodalumab: 4-Year US Pharmacovigilance Report
Mark Lebwohl, John Koo, Craig L. Leonardi, April W. Armstrong et autres
20 citationsJournal of Drugs in Dermatology
34658 Deucravacitinib, an oral, selective tyrosine kinase 2 (TYK2) inhibitor, in patients with moderate to severe plaque psoriasis who had inadequate responses to apremilast at week 24 in the phase 3 POETYK PSO-1 and PSO-2 trials
April W. Armstrong, Richard B. Warren, Howard Sofen, Lynda Spelman et autres
2 citationsJournal of the American Academy of Dermatology
34346 Pooled safety analysis of respiratory tract infections, including COVID-19, in psoriasis patients treated with secukinumab
Hendrik Schulze‐Koops, Atul Deodhar, Reinhard Voll, Jan Leipe et autres
0 citationsJournal of the American Academy of Dermatology
34314 Bimekizumab comparative efficacy in psoriasis: Number needed to treat analyses of phase 3/3b trial data
Craig L. Leonardi, April Armstrong, Kilian Eyerich
0 citationsJournal of the American Academy of Dermatology
Wolf’s isotopic response of lichen planus following contact dermatitis
Bruin Pollard, William H. McCoy, Craig L. Leonardi, Ann Martin
1 citationJAAD Case Reports
Efficacy of Bimekizumab and Other Biologics in Moderate to Severe Plaque Psoriasis: A Systematic Literature Review and a Network Meta-Analysis
April W. Armstrong, Kyle Fahrbach, Craig L. Leonardi, Matthias Augustin et autres
62 citationsDermatology and Therapy
Real-World Biologic Adherence, Persistence, and Monotherapy Comparisons in US Patients with Psoriasis: Results from IBM MarketScan® Databases
Craig L. Leonardi, Baojin Zhu, William N. Malatestinic, William Eastman et autres
17 citationsAdvances in Therapy
Number Needed to Treat Network Meta-Analysis to Compare Biologic Drugs for Moderate-to-Severe Psoriasis
Craig L. Leonardi, Kyoungah See, Russel Burge, Zhuoer Sun et autres
25 citationsAdvances in Therapy
Three‐year U.S. pharmacovigilance report of brodalumab
Mark Lebwohl, Craig L. Leonardi, April W. Armstrong, Nicole Rawnsley et autres
20 citationsDermatologic Therapy
24899 Ixekizumab sustains high efficacy and a favorable safety profile in burdensome areas in patients with moderate-to-severe psoriasis: 5-year results from UNCOVER-2
Kim Papp, Andrew Blauvelt, L. Puig, Hany Elmaraghy et autres
0 citationsJournal of the American Academy of Dermatology
Psoriasis treatment patterns and outcomes with ixekizumab in a real-world setting: results from a single US dermatology referral practice
Craig L. Leonardi, Rei Tao, Solmaz Setayeshgar, Sisi Wang et autres
2 citationsJournal of Dermatological Treatment
BNTIC News n’est pas le producteur de ces données. Recherche à la demande dans Crossref et Europe PMC, sans clé ; OpenAlex reste optionnel. Aucun service payant requis, aucune réponse conservée. Sources et limites.